拉贝洛尔与尼卡地平在脑出血中的院内感染风险比较
本研究基于单中心前瞻性数据的回顾性分析,纳入1066例脑出血住院患者中525例接受拉贝洛尔或尼卡地平治疗者。
要点
- 单用拉贝洛尔较单用尼卡地平与院内感染风险升高相关(OR 3.12)。
- 拉贝洛尔联合尼卡地平与感染关联无统计学意义(OR 2.44,P=0.055)。
- 拉贝洛尔无论是否联用尼卡地平,均未增加死亡或不良功能结局风险。
核心结论
- 与尼卡地平相比,拉贝洛尔与院内感染增加相关,但未增加死亡率或出院mRS>2风险。
研究设计与样本
- 单中心前瞻性数据的回顾性分析,纳入住院前3天使用拉贝洛尔、尼卡地平或两者联用的脑出血患者。
- 共1066例入院患者中525例纳入分析,229例(43.6%)用拉贝洛尔,107例(20.4%)用尼卡地平,189例(36.0%)两者联用。
- 采用倾向评分比较,并用线性模型校正显著混杂因素。
主要发现
- 总体死亡率40.2%,感染率15.8%,77.2%患者出院mRS>2。
- 拉贝洛尔(无论是否联用尼卡地平)与死亡或出院mRS>2无显著关联。
临床怎么用
- 脑出血降压治疗选择尼卡地平可能较拉贝洛尔减少院内感染风险,但需结合个体情况权衡。
- 使用拉贝洛尔时应加强感染监测与预防措施。
局限性
- 单中心回顾性设计可能引入选择偏倚和残余混杂。
- 样本量有限,联合用药组感染关联未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Increased sympathetic tone causes hypertension after intracerebral hemorrhage, and blood pressure reduction has been studied as a way to decrease hemorrhage growth and improve outcomes. It is unknown if the antihypertensive used to achieve blood pressure goals influences either. Because sympatholytic drugs reduce death and infection in animal models, we hypothesized that labetalol would improve outcomes compared with nicardipine. METHODS: Prospective data from a single center were retrospectively reviewed. Patients receiving labetalol, nicardipine, or both during their first 3 days of hospitalization were included. Outcomes included in-hospital death; discharge modified Rankin Score >2; and in-hospital urinary tract infection, pneumonia, or bacteremia. Patients were compared with propensity scoring and analyzed with linear models adjusted for significant confounders. RESULTS: Of 1066 admissions, 525 were treated with labetalol or nicardipine and are included; 229 (43.6%) received labetalol, 107 (20.4%) received nicardipine, and 189 (36.0%) received both. Mortality and infection rates were 40.2% and 15.8%, respectively, 77.2% had a modified Rankin Score >2. After adjustment, compared with nicardipine alone, labetalol alone was associated with infection (odds ratio, 3.12; confidence interval, 1.27-7.64; P=0.013) but not when combined with nicardipine (odds ratio, 2.44; confidence interval, 0.98-6.07; P=0.055). Labetalol, with or without nicardipine, was not associated with death or discharge modified Rankin Score >2. CONCLUSIONS: Compared with nicardipine, labetalol was associated with increased in-hospital infections, but not mortality or modified Rankin Score >2. These findings do not support our hypothesis that labetalol use improves outcomes relative to nicardipine in intracerebral hemorrhage.
引用
- Starr JB, Tirschwell DL, Becker KJ, et al. Labetalol Use Is Associated With Increased In-Hospital Infection Compared With Nicardipine Use in Intracerebral Hemorrhage. Stroke. 2017. PMID: 28904237. doi:10.1161/STROKEAHA.117.017230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。